CoChat

Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia

Open access

The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.

Abstract

PURPOSE: Sarcopenia is an age-related muscle condition which is frequently a precursor of frailty, mobility disability and premature death. It has a high prevalence in older populations and presents a considerable social and economic burden. Potential treatments are under development but, as yet, no guidelines support regulatory studies for new drugs to manage sarcopenia. The objective of this position paper is therefore to suggest a set of potential endpoints and target population definitions to stimulate debate and progress within the medico-scientific and regulatory communities. METHODS: A multidisciplinary expert working group was hosted by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, which reviewed and discussed the recent literature from a perspective of clinical experience and guideline development. Relevant parallels were drawn from the development of definition of osteoporosis as a disease and clinical assessment of pharmaceutical treatments for that indication. RESULTS: A case-finding decision tree is briefly reviewed with a discussion of recent prevalence estimations of different relevant threshold values. The selection criteria for patients in regulatory studies are discussed according to the aims of the investigation (sarcopenia prevention or treatment) and the stage of project development. The possible endpoints of such studies are reviewed and a plea is made for the establishment of a core outcome set to be used in all clinical trials of sarcopenia. CONCLUSIONS: The current lack of guidelines for the assessment of new therapeutic treatments for sarcopenia could potentially hinder the delivery of effective medicines to patients at risk.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40520-015-0517-y

Cites

93 of 93 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 The application of the OMERACT filter 2.0 for the definition of core outcomes for sarcopenia. ICF International Classification of Functioning, Disability and Health framework of the World Health Organisation
Fig. 1 The application of the OMERACT filter 2.0 for the definition of core outcomes for sarcopenia. ICF International Classification of Functioning, Disability and Health framework of the World Health OrganisationCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 93 references

Cited by

See all 116

Metadata

Authors
Reginster, J.-Y., Cooper, C., Rizzoli, R., Kanis, J. A., Appelboom, G., Bautmans, I., Bischoff-Ferrari, H. A., Boers, M., Brandi, M. L., Bruyère, O., Cherubini, A., Flamion, B., Fielding, R. A., Gasparik, A. I., Van Loon, L., McCloskey, E., Mitlak, B. H., Pilotto, A., Reiter-Niesert, S., Rolland, Y., Tsouderos, Y., Visser, M., & Cruz-Jentoft, A. J.
Affiliations
  • University of Liège (BE)
  • University of Oxford (GB)
  • University of Geneva (CH)
  • Columbia University Irving Medical Center (US)
  • Vrije Universiteit Brussel (BE)
  • University Hospital Zurich (CH)
  • Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
  • University of Florence (IT)
  • Istituto Nazionale di Riposo e Cura per Anziani (IT)
  • University of Namur (BE)
  • Tufts University (US)
  • University of Sheffield (GB)
  • Eli Lilly (United States) (US)
  • Ente Ospedaliero Ospedali Galliera (IT)
  • Université de Toulouse (FR)
  • Institut de Recherches Internationales Servier (France) (FR)
  • Vrije Universiteit Amsterdam (NL)
  • Hospital Universitario Ramón y Cajal (ES)
Corresponding author
Bruyère, Olivier
Venue
Aging Clinical and Experimental Research
Published
2015-12-30
Volume
28
Issue
1
Pages
47-58
ISSN
  • 1594-0667 (ISSN-L)
  • 1720-8319
OpenAlex
W2214973932
Cited by
112
References
93
Citations by year
2026: 1 · 2025: 1 · 2024: 15 · 2023: 8 · 2022: 15 · 2021: 12 · 2020: 7 · 2019: 13 · 2018: 14 · 2017: 16 · 2016: 10
FWCI
1.64
Type
journal article
Language
en
Open access
Licence
Locations
  • Aging Clinical and Experimental Research (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research Publications (Maastricht University) (publishedVersion, cc-by)
  • Pure Amsterdam UMC (publishedVersion, other-oa)
  • VU Research Portal (publishedVersion, other-oa)
  • Archive ouverte UNIGE (University of Geneva) (publishedVersion)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
  • ePrints Soton (University of Southampton) (acceptedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
  • Research Bank (Australian Catholic University) (submittedVersion)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
  • Florence Research (University of Florence) (submittedVersion)
  • Università Politecnica delle Marche (Università Politecnica delle Marche) (submittedVersion)
  • Open Repository and Bibliography (University of Liège) (submittedVersion)
  • CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion, other-oa)
  • Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
  • VUBIR (Vrije Universiteit Brussel) (submittedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
Funders
  • Medical Research and Materiel Command, U.S. Army Medical Department
  • US Department of Agriculture
Topics
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
Keywords
sarcopenia, clinical trial design, drug development, sarcopenia prevention, core outcome set, clinical trial endpoints, patient selection criteria, sarcopenia prevalence, regulatory guidelines, frailty, older adults
MeSH terms
Aged, Clinical Trials as Topic, Humans, Research Design, Practice Guidelines as Topic, Medication Therapy Management, Sarcopenia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia. https://app.cochat.ai/papers/10.1007/s40520-015-0517-y
The paper
Reginster, J.-Y., Cooper, C., Rizzoli, R., Kanis, J. A., Appelboom, G., Bautmans, I., Bischoff-Ferrari, H. A., Boers, M., Brandi, M. L., Bruyère, O., Cherubini, A., Flamion, B., Fielding, R. A., Gasparik, A. I., Van Loon, L., McCloskey, E., Mitlak, B. H., Pilotto, A., Reiter-Niesert, S., . . . Cruz-Jentoft, A. J. (2016). Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia. Aging Clinical and Experimental Research. https://doi.org/10.1007/s40520-015-0517-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.